ALMR Alamar Biosciences, Inc.
Fundamentals / CIK 0002104204 / USDAlamar Biosciences, Inc. reported $378.0M in total assets through September 30, 2026 from SEC EDGAR filings.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open ALMR in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2026-- Sep 30, 2026
-
Operating Income FY 2026-- Operating profit
-
Net Income FY 2026-- GAAP bottom line
-
Diluted EPS FY 2026-- Split-adjusted
-
Free Cash Flow FY 2026-- Operating CF less CapEx
-
Cash & ST Investments Sep 30, 2026$226.6M Total debt: $42.35M
Financial statements and ratios
Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in USD · Newest filing period first.
Income Statement (Quarterly) · Reported in USD · Newest filing period first.
| Income Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Revenue | $33.55M | $29.43M | $26.04M | $19.91M | $16.16M | $13.09M |
| Cost of Revenue | $12.90M | $11.71M | $11.58M | $8.02M | $7.58M | $6.70M |
| Gross Profit | $20.64M | $17.72M | $14.46M | $11.90M | $8.58M | $6.39M |
| Research & Development | $16.17M | $13.82M | $13.02M | $10.21M | $8.89M | $8.30M |
| Selling, General & Admin | $19.62M | $17.43M | $13.79M | $9.58M | $7.61M | $6.64M |
| Total Operating Expenses | $35.78M | $31.25M | $26.80M | $19.78M | $16.50M | $14.94M |
| Operating Income | -$15.14M | -$13.53M | -$12.35M | -$7.88M | -$7.92M | -$8.55M |
| EBITDA | -$13.71M | -$12.40M | -$11.18M | -$6.90M | -$7.00M | -$7.67M |
| Interest Income | $2.17M | $1.88M | $539K | $410K | $630K | $786K |
| Income Before Tax | -$13.25M | -$13.29M | -$20.86M | -$7.56M | -$7.02M | -$7.66M |
| Income Tax Expense | $94K | -$93K | $464K | $440K | -- | -- |
| Net Income | -$13.34M | -$13.20M | -$21.32M | -$8.00M | -$7.02M | -$7.66M |
| Basic EPS | -$0.19 | -$0.22 | -$1.74 | -$0.69 | -$0.62 | -$0.68 |
| Diluted EPS | -$0.19 | -$0.22 | -$1.74 | -$0.69 | -$0.62 | -$0.68 |
| Basic Shares Outstanding | 69.1M | 58.7M | 12.3M | 11.6M | 11.4M | 11.3M |
| Diluted Shares Outstanding | 69.1M | 58.7M | 12.3M | 11.6M | 11.4M | 11.3M |
Balance Sheet (Annual) · Reported in USD · Newest filing period first.
Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.
| Balance Sheet | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|---|
| Cash & Cash Equivalents | $121.5M | $133.0M | $64.59M | $30.00M |
| Short-Term Investments | $105.1M | $117.1M | $0 | $0 |
| Cash & Short-Term Investments | $226.6M | $250.1M | $64.59M | $30.00M |
| Accounts Receivable, Net | $21.61M | $20.34M | $19.52M | $12.75M |
| Inventory | $54.13M | $45.41M | $39.93M | $38.48M |
| Total Current Assets | $317.7M | $331.4M | $141.5M | $94.70M |
| Property, Plant & Equipment, Net | $15.24M | $13.36M | $10.47M | $10.50M |
| Long-Term Investments | -- | -- | $0 | $0 |
| Other Non-Current Assets | $2.51M | $2.58M | $2.09M | $1.76M |
| Total Non-Current Assets | $60.34M | $59.59M | $44.98M | $45.29M |
| Total Assets | $378.0M | $391.0M | $186.5M | $140.0M |
| Accounts Payable | $16.55M | $13.79M | $5.63M | $5.87M |
| Deferred Revenue (Current) | $1.78M | $2.19M | $2.11M | $470K |
| Total Current Liabilities | $33.48M | $27.96M | $24.05M | $23.73M |
| Other Non-Current Liabilities | $974K | $1.03M | $1.20M | $599K |
| Total Non-Current Liabilities | $40.84M | $50.16M | $105.5M | $40.22M |
| Total Liabilities | $74.32M | $78.12M | $129.5M | $63.95M |
| Total Debt (incl. Leases) | $42.35M | $41.46M | $30.58M | $31.66M |
| Common Stock | $7.0K | $7.0K | $1.0K | $1.0K |
| Retained Earnings | -$216.6M | -$203.3M | -$190.1M | -$168.8M |
| Accumulated Other Comp. Income | -$173K | -$139K | -$80K | -$72K |
| Total Stockholders' Equity | $303.7M | $312.9M | -$178.1M | -$159.0M |
| Total Equity | $303.7M | -$312.9M | -$178.1M | -$159.0M |
Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.
Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.
| Cash Flow Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Net Income | -$13.34M | -$13.20M | -$21.32M | -$8.00M | -$7.02M | -$7.66M |
| Depreciation & Amortization | $1.42M | $1.13M | $1.17M | $983K | $919K | $888K |
| Stock-Based Compensation | $3.92M | $3.28M | $1.47M | $705K | $680K | $619K |
| Change in Receivables | -$1.32M | -$967K | -$6.85M | -$956K | -$2.32M | -$533K |
| Change in Inventory | -$10.21M | -$5.72M | -$1.26M | -$9.44M | -$7.06M | -$2.36M |
| Change in Payables | $1.63M | $6.32M | $1.34M | $3.22M | -$1.81M | $578K |
| Operating Cash Flow | -$14.73M | -$11.32M | -$20.35M | -$14.14M | -$11.88M | -$13.07M |
| Capital Expenditure | -$463K | -$3.64M | -$600K | -$1.22M | -$753K | -$554K |
| Free Cash Flow | -$15.20M | -$14.96M | -$20.95M | -$15.36M | -$12.63M | -$13.62M |
| Investing Cash Flow | $11.74M | -$120.8M | -$778K | $14.19M | $17.95M | $17.02M |
| Financing Cash Flow | -$9.85M | $201.8M | $55.76M | $10.40M | $164K | $243K |
| Net Change in Cash | -$12.78M | $69.73M | $34.58M | $9.98M | $6.56M | $4.33M |
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.
| Ratios & Growth | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Current Ratio | 9.49x | 11.85x | 5.88x | -- | -- | -- |
| Quick Ratio | 7.87x | 10.23x | 4.22x | -- | -- | -- |
| Debt to Equity | 0.14x | 0.13x | -- | -- | -- | -- |
| Revenue Growth (YoY) | +68.5% | +82.1% | +98.9% | -- | -- | -- |
| Gross Profit Growth (YoY) | +73.5% | +106.5% | +126.3% | -- | -- | -- |